Incyte to Present New Data at European Dermatology Congress 2025
24-week data from the Phase 3 STOP-HS clinical trial program of povorcitinib in patients with hidradenitis suppurativa (HS) selected as a late-breaking oral presentation Today...
Category : Clinical Research, Pharma & Healthcare Financing
CAPVAXIVE® Shows Positive Immune Response in At-Risk Youth
Results from the Phase 3 STRIDE-13 trial presented at the 6th ESCMID Conference on Vaccines Merck to share STRIDE-13 results with global regulatory authorities Merck (NYSE:...
Seegene, Springer Nature Open 2025–26 MDx Grant Applications
The program focuses on antibiotic resistance in urinary tract infections (UTI-DR), with applications open until November 20; final awardees to be announced in August 2026Selected researchers will...
Valo Health Awarded Grant to Advance Parkinson’s Disease Research
Valo to leverage human causal biology expertise to uncover new insights about NOD2 as a potential Parkinson’s disease drug target Valo Health, Inc. (“Valo”), a company...
Vyome Holdings Adds Industry Veterans as It Plans Pivotal Trial Studies
Dr. Richard Fahrner and Dr. Tamara Agajanov add expertise in accelerated approvals Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced the...
Precision BioSciences Secures U.S. Patent for PBGENE-HBV
Strengthens the Company’s intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection into 2042 Phase 1 ELIMINATE-B trial progressing through clinical...
Regeneron Reports Positive Phase 3 Data for Allergy Antibodies
In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo Data from these trials will...
IDEAYA Reports Positive Phase 2 Data for Darovasertib in UM
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, will present positive interim data at their 10-Year Anniversary R&D Day from their ongoing Phase...
Lilly’s Jaypirca Improves Survival in CLL/SLL Patients
In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine plus rituximab,...
FDA Accepts LSM by VCTE as Surrogate Endpoint in MASH Trials
This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development Echosens, the leader...
Biocodex Invests €30M in MRM Health Microbiome Therapy
Biocodex, a French family-owned pharmaceutical pioneer in microbiota research for over 70 years, announces a strategic equity investment of €11 million in MRM Health, a...
New Data Reinforce Genentech’s Vabysmo Efficacy & Safety
In AVONELLE-X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on...
Nature Medicine Publishes Phase 3 Data on Pridopidine
Treatment with pridopidine slowed clinical progression and maintained function, cognition, and motor performance in pre-defined analyses of a subgroup of early-stage Huntington’s disease (HD) patients...
Stallergenes Greer & Nuance Pharma Partner for Actair in China
Stallergenes Greer, a global leader in allergy therapeutics, and Nuance Pharma, an innovation-focused biopharmaceutical company based in China, today announced they have entered into an...
Travere Therapeutics Presents at Inborn Errors Congress
Presentation details long-term safety and efficacy data on pegtibatinase as a potential treatment for classical HCU Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the...